Importantly, targeting of the FGF19–receptor axis by ponatinib, a third-generation inhibitor of chronic myeloid leukemia, overcomes the HCC resistance of sorafenib by enhancing ROS-associated apoptosis in sorafenib-treated HCC [144]. Here, FGF19 is linked to hepatocellular carcinoma.